DNA-Binding Anticancer Drugs: One Target, Two Actions

DNA-Binding Anticancer Drugs: One Target, Two Actions

Amsacrine, an anticancer drug first synthesised in 1970 by Professor Cain and colleagues, showed excellent preclinical activity and underwent clinical trial in 1978 under the auspices of the US National Cancer Institute, showing activity against acute lymphoblastic leukaemia. In 1984, the enzyme DNA...

Full description

Bibliographic Details
Main Authors: Bruce C. Baguley, Catherine J. Drummond, Ying Yi Chen, Graeme J. Finlay
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Molecules
Subjects:
DNA binding
antitumour
topoisomerase
cell cycle
pharmacokinetics
immunogenic cell death
Online Access:https://www.mdpi.com/1420-3049/26/3/552

Internet

https://www.mdpi.com/1420-3049/26/3/552

Similar Items